The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).
Topic Depression
Country United States of America
Visit trial
Status
Completed
Results Published
Start date
10 January 2011
End date
10 January 2014
Chance of happening
100%
Phase
Not Applicable
Design
Blinded
Type
Interventional
Generation
First
Participants
20
Sex
All
Age
21- 65
Therapy
No
Trial Details
The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).NCT Number NCT01304147
Sponsors & Collaborators
Icahn School of Medicine at Mount SinaiThis company doesn't have a full profile yet, it is linked to a clinical trial.
Measures Used
Montgomery-Asberg Depression Rating ScaleA ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.